Oxford Brain Diagnostics hopes to commercialise an early diagnosis tool for Alzheimer’s disease pioneered through eight years of University of Oxford research.

Oxford Brain Diagnostics, a UK-based neurodegenerative disorder diagnostics spinout from University of Oxford, today received an undisclosed amount of capital from university co-investment vehicle University of Oxford Innovation Fund (UOIF) IV.
UOIF IV is managed by Parkwalk Advisors, the fund management arm of commercialisation firm IP Group, on behalf of the university.
Founded in November 2018, Oxford Brain Diagnostics has devised an early diagnosis tool that could help predict whether patients suffering from mild memory issues will go on to develop cognitive conditions such as Alzheimer’s disease, which causes dementia.
The system, dubbed Cortical Disarray Measurement (CDM), works by inspecting alterations within the microscopic structures in brain tissue, based on information collected from standard MRI scans.
CDM will initially focus on catching Alzheimer’s disease for purposes including pharmaceuticals development but could in time be expanded to diagnose other brain conditions and to meet applications in new markets.
The technology is the result of an eight-year research collaboration between Steven Chance, an associate professor in clinical neurosciences at University of Oxford’s medical sciences division, and Mark Jenkinson, professor of neuroimaging at the university’s Oxford Centre for Functional MRI of the Brain.